News Releases

There are currently no events to display.
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Read More
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Read More
Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
Read More
Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
Read More
Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
Read More
Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Read More
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Read More
Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
Read More
Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Read More
Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
Read More
Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
Read More
Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
Read More
Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association
Read More
Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology
Read More
Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Read More
Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association
Read More
Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Read More
Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Read More
Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting
Read More
Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer
Read More
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Read More
Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
Read More
Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting
Read More
Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Read More
Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Read More
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Read More
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Read More
Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
Read More
Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
Read More